Simulations Plus SLP Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

NeoGenomicsNEO

——

Medpace Holdings, Inc.MEDP

——

Other financials

Income statement

See full

Revenue$24.3M+8.3%

Gross profit$16.1M+23.0%

Operating income$5.6M+108%

Net income$4.5M+47.5%

EPS (diluted)$0.22+46.7%

Balance sheet

See full

Cash & equivalents$25.7M+134%

Total debt$508.0K-36.2%

Total equity$133.8M-29.4%

Total assets$146.5M-27.3%

Cash flow

See full

Operating cash flow$6.4M+13.1%

CapEx$46.0K-30.3%

Free cash flow$6.4M+13.6%

Valuation

See full

Market cap$366.73M+5.2%

Enterprise value$341.51M+6.0%

P/S4.6×+0.2×

Profitability

See full

Gross margin62%+6.7pp

Operating margin-84.3%—

Net margin-78%-87.2pp

FCF margin29.5%+14.9pp

Returns & leverage

See full

Return on equity-38.8%-42.8pp

Debt / equity0×0.0×

Current ratio5.5×+1.1×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Simulations Plus’s 10-Q, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Simulations Plus's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Simulations Plus's share based compensation arrangement by share based payment award options exercisable number?: Simulations Plus (SLP) reported share based compensation arrangement by share based payment award options exercisable number of $1.12M in Q4 2025.